Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**bCalm** is a NuLife Sciences oral nutraceutical dietary supplement marketed under the company's microvascular health and wellness portfolio, but the product-specific positioning identified in the provided context is for emotional health rather than a defined microvascular indication. The active ingredient is reported to correspond 100% to **inositol**, commonly described in supplement marketing as vitamin B8, and it is promoted to calm the mind and body naturally and support tranquility and overall wellness. Mechanistically, bCalm appears to function as an **inositol supplement** rather than a pharmaceutical drug with a validated single molecular target; any anxiolytic or metabolic effects would be attributed to inositol's role as an endogenous carbohydrate involved in phosphoinositide and second-messenger signaling, but no specific clinical development program or drug pipeline evidence was identified for bCalm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bCalm.